GW501516 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic PPARδ agonist | Not a steroid or a selective androgen receptor modulator. |
| Common synonyms | Cardarine, GW501516, GW-501516, endurobol | Names vary by supplier and literature source. |
| Appearance | White to off-white powder | Consistent with many small-molecule research chemicals. |
| Solubility | Low in water; soluble in DMSO and ethanol | Often prepared in organic solvent for laboratory work. |
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid and energy metabolism. |
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
== Further reading == Alberts, B. et al. (2002). Molecular Biology of the Cell, 4th ed. New York: Garland Science. ISBN 0-8153-3218-1. Berg, J. M. et al. (2002). Biochemistry, 5th ed. New York: W.H. Freeman and Company. ISBN 0-7167-3051-0. Singh, B. D. (2002). Fundamentals of Genetics, New Delhi, India: Kalyani Publishers. ISBN 81-7663-109-4.
Many white Southern Christians, including church ministers, attempted to justify their support for slavery as modified by Christian paternalism. The largest denominations, the Baptist, Methodist, and Presbyterian churches, split over the slavery issue into regional organizations of the North and South.
== Costs == Bone graft procedures consist of more than just the surgery itself. The complete three-month total cost of a complex posterolateral lumbar spine fusion bone graft supplemented with graft extenders ranges from a mean of approximately US$33,860 to US$37,227. This price includes all visits in and out of the hospital for three months. Besides the cost of the bone graft itself (ranging from US$250 to US$900) other expenses for the procedure include: outpatient rehabilitation fees (US$5,000 to US$7,000), screws and rods (US$7,500), room and board (US$5,000), operating room (US$3,500), sterile supplies (US$1,100), physical therapy (US$1,000), surgeon's fees (average US$3,500), anesthesiologist fees (approximately US$350 to US$400 per hour), medication charges (US$1,000), and additional fees for services such as medical supplies, diagnostic procedures, equipment use fees, etc.
The jury acquitted Letby of the attempted murder on counts 9 (Baby G) and 10 (Baby H), and was unable to reach verdicts on counts 11 (Baby H), 13 (Baby J), 14, (Baby K), 18 and 19 (Baby N), and 22 (Baby Q). On 21 August 2023, Letby was sentenced to life imprisonment with a whole life order, the most severe penalty available under English law. She became the fourth woman in the UK to receive such a sentence. In his remarks, Goss described her actions as "a cruel, calculated and cynical campaign of child murder involving the smallest and most vulnerable of children", adding that "there was a deep malevolence bordering on sadism [...] you [Letby] have no remorse [...] there are no mitigating factors [...] the offences are of sufficient severity to require a whole life order." Letby chose not to attend the sentencing hearing and therefore did not hear the victim impact statements or the sentence being passed. In response, the Secretary of State for Justice, Alex Chalk, said the government would "look at options to change the law at the earliest opportunity" to require defendants to attend their sentencing. Following the trial, Letby was transferred to HMP Low Newton in County Durham. As of February 2025, she is held at HM Prison Bronzefield.
=== Contraindications === The use of lysine vasopressin is contraindicated in the presence of hypersensitivity to beef or pork proteins, increased BUN and chronic kidney failure. It is recommended that it be cautiously used in instances of perioperative polyuria, sensitivity to the drug, asthma, seizures, heart failure, a comatose state, migraine headaches, and cardiovascular disease.
Sources: en.wikipedia.org
The Ministry also indicated it had captured 4 of the Comandos de la Frontera, who were later released. The United States Department of Defense, did not comment as an investigation into the event is ongoing, but referred the matter to the Office of the Director of National Intelligence for further questions. In January 2026, an Ecuadorian fishing vessel, carrying eight crew members disappeared, while two other crew member were away. When they returned to the boat's last know location, there was no sign of it and it is unknown what happened to it. In March, two Ecuadorian fishing vessels near the Galápagos Islands in Ecuador's exclusive economic zone were attacked and damaged by small, explosive-laden rotor drones. In both these incidents, the crews reported being later taken aboard a U.S. military vessel and later transferred to El Salvador and handed over to the authorities there, before being returned to Ecuador. The Washington Post reported in August that the two Galápagos boat strikes were part of a covert CIA program, although CNN said they could not independently verify this. While the US has admitted attacking dozens of alleged drug-trafficking vessels in the Caribbean and Pacific, they have denied responsibility for these incidents. Ecuadorian authorities have also largely not commented on them. In late August, the U.S., in collaboration with Ecuador, began sinking Ecuadorian vessels alleged to be involved drug traffickiing. Within two weeks, six vessels were sunk, with the crews being removed and transferred to Ecuadorian authorities before the boats were sunk.
In mass spectrometry, data-independent acquisition (DIA) is a method of molecular structure determination in which all ions within a selected m/z range are fragmented and analyzed in a second stage of tandem mass spectrometry. Tandem mass spectra are acquired either by fragmenting all ions that enter the mass spectrometer at a given time (called broadband DIA) or by sequentially isolating and fragmenting ranges of m/z. DIA is an alternative to data-dependent acquisition (DDA) where a fixed number of precursor ions are selected and analyzed by tandem mass spectrometry.
Tizanidine, sold under the brand names Zanaflex and Sirdalud among others, is an α2-adrenergic receptor agonist and muscle relaxant which is used to treat muscle spasticity due to spinal cord injury, multiple sclerosis, and spastic cerebral palsy. Its effectiveness appears to be similar to that of other muscle relaxants like baclofen or diazepam. The drug is taken orally. Common side effects of tizanidine include sleepiness, dry mouth, asthenia, dizziness, low blood pressure, and low heart rate. Serious side effects may include dangerously low blood pressure, liver problems, and psychosis. It is unclear if use in pregnancy and breastfeeding is safe. The drug is an α2-adrenergic receptor agonist, but how it works is not entirely clear. Tizanidine was approved for medical use in the United States in 1996. It is available as a generic medication. In 2023, it was the 81st most commonly prescribed medication in the United States, with more than 8 million prescriptions.
Some nuclei can undergo double beta decay (2β) where the charge of the nucleus changes by two units. Double beta decay is difficult to study, as it has an extremely long half-life. In nuclei for which both β decay and 2β are possible, the rarer 2β process is effectively impossible to observe. However, in nuclei where β decay is forbidden but 2β is allowed, the process can be seen and a half-life measured. Thus, 2β is usually studied only for beta stable nuclei. Like single beta decay, double beta decay does not change A; thus, at least one of the nuclides with some given A has to be stable with regard to both single and double beta decay. "Ordinary" 2β results in the emission of two electrons and two antineutrinos. If neutrinos are Majorana particles (i.e., they are their own antiparticles), then a decay known as neutrinoless double beta decay will occur. Most neutrino physicists believe that neutrinoless 2β has never been observed.
VP-13 operating PB2Y-3s from 26 February to 22 June 1944 VP-16 operating PBM-3Ds from 7 June to 1 August 1944 VP-21 operating PBM-3Ds from 19 August to 17 October 1944 and from 15 July to 11 September 1945 VP-23 operating PBY-5As from 20 August 1944 to 9 April 1945 VP-MS-6 operating PBM-5Es from 1 February 1948 in support of Operation Sandstone VP-102 operating PB2Y-3s from 3 February to 30 August 1944 VP-202 operating PBM-3Ds from 24 February to 1 March 1944 VPB-19 operating PBM-3Ds from 2 November 1944 to 12 February 1945 and 6 March 1945 to January 1946 VPB-22 operating PBM-3Ds from 10 October to 30 November 1944 and from 25 June to 7 August 1945
Sources: en.wikipedia.org
As the organic tin compound, a trimethylstannyl or tributylstannyl compound is normally used. Although trimethylstannyl compounds show higher reactivity compared with tributylstannyl compounds and have much simpler 1H-NMR spectra, the toxicity of the former is much larger. Optimizing which ligands are best at carrying out the reaction with high yield and turnover rate can be difficult. This is because the oxidative addition requires an electron rich metal, hence favoring electron donating ligands. However, an electron deficient metal is more favorable for the transmetalation and reductive elimination steps, making electron withdrawing ligands the best here. Therefore, the optimal ligand set heavily depends on the individual substrates and conditions used. These can change the rate determining step, as well as the mechanism for the transmetalation step. Normally, ligands of intermediate donicity, such as phosphines, are utilized. Rate enhancements can be seen when moderately electron-poor ligands, such as tri-2-furylphosphine or triphenylarsenine are used. Likewise, ligands of high donor number can slow down or inhibit coupling reactions. These observations imply that normally, the rate-determining step for the Stille reaction is transmetalation.
The only prediction that can be made is statistical and expresses an average rate of decay. This rate can be represented by adjusting the curve of a decaying exponential distribution with a decay constant (λ) particular to the isotope. On this understanding the radioactive decay of an initial population of unstable atoms over time t follows the curve given by e−λt. One of the most important properties of any radioactive material follows from this analysis, its half-life. This refers to the time required for half of a given number of radioactive atoms to decay and is inversely related to the isotope's decay constant, λ. Half-lives have been determined in laboratories for many radionuclides, and can range from nearly instantaneous—hydrogen-5 decays in less time than it takes for a photon to go from one end of its nucleus to the other—to fourteen orders of magnitude longer than the age of the universe: tellurium-128 has a half-life of 2.2×1024 years.
Montirelin (also known as CG-3703 or NS-3) is a synthetic analogue of thyrotropin-releasing hormone (TRH), designed to enhance central nervous system stimulation with greater potency and duration than natural TRH. Montirelin binds to TRH receptors in the brain, stimulating the release of thyrotropin (TSH) and prolactin. It exhibits sustained receptor occupancy and a counter-clockwise hysteresis between plasma concentration and receptor binding, suggesting prolonged CNS activity. Montirelin has demonstrated efficacy in animal models for:
There is extensive experience, over many years, of the use of radioiodine in the treatment of thyroid overactivity, and this experience does not indicate any increased risk of thyroid cancer following treatment. However, a study from 2007 has reported an increased number of cancer cases after radioiodine treatment for hyperthyroidism. The principal advantage of radioiodine treatment for hyperthyroidism is that it tends to have a much higher success rate than medications. Depending on the dose of radioiodine chosen, and the disease under treatment (Graves' vs. toxic goiter, vs. hot nodule, etc.), the success rate in achieving definitive resolution of the hyperthyroidism may vary from 75 to 100%. A major expected side-effect of radioiodine in people with Graves' disease is the development of lifelong hypothyroidism, requiring daily treatment with thyroid hormone. On occasion, some people may require more than one radioactive treatment, depending on the type of disease present, the size of the thyroid, and the initial dose administered. People with Graves' disease manifesting moderate or severe Graves' ophthalmopathy are cautioned against radioactive iodine-131 treatment, since it has been shown to exacerbate existing thyroid eye disease. People with mild or no ophthalmic symptoms can mitigate their risk with a concurrent six-week course of prednisone. The mechanisms proposed for this side effect involve a TSH receptor common to both thyrocytes and retro-orbital tissue.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.
It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.
No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.